Business
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - JERUSALEM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U8Q3xNkSuAPosRUnHeWZmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"- First patient in the world treated with Alpha DaRT® in the brain –","length":68,"tagName":"p"},{"type":"text","content":"- According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months –","length":189,"tagName":"p"},{"type":"text","content":"- This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - ","length":142,"tagName":"p"},{"type":"image","alt":"Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial","displaySize":"","headline":null,"caption":"Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial","className":"","disableSlideshowImg":false,"size":{"original":{"width":1080,"height":1080,"url":"https://media.zenfs.com/en/globenewswire.com/dbd99cf9ef2374e3bebc4babe8c5cb08"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DWc_cqXLx_IdEiSgdEH8oA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dbd99cf9ef2374e3bebc4babe8c5cb08","width":960,"height":960},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hrLS2aO1AYtlbz4tjRDYmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxNjA7aD0yMTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/dbd99cf9ef2374e3bebc4babe8c5cb08","width":1080,"height":1080}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"JERUSALEM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the first patient has been treated in its pilot study for the treatment of patien...